Table 4.

Multivariate analysis of the risk factors for developing PTGN.

	Regression estimate (B)	Relative risk (95% CI), Exp B	P
Recipient age, years
<20	–	1
20–30	–0.929	0.40 (0.152–1.03)	0.057
31–40	–0.512	0.60 (0.26–1.39)	0.231
41–50	–0.330	0.72 (0.25–2.1)	0.540
>50	0.793	0.45 (0.039–5.23)	0.525
Original kidney disease
No GN	–	1
GN	0.015	1.01 (0.566–1.821)	0.959
Donor age, years
<30	–	1
31–40	0.570	1.76 (1.04–3)	0.035
41–50	0.602	1.82 (0.977–3.41)	0.059
>50	0.289	1.33 (0.657–2.71)	0.424
Recipient sex match
Male–male	–	1
Male–female	–0.228	0.796 (0.319–1.98)	0.625
Female–male	0.397	1.48 (0.743–2.97)	0.263
Female–female	0.451	1.57 (0.576–4.27)	0.378
Consanguinity
Parent	–	1
Sibling	0.518	1.67 (0.47–5.97)	0.424
Off-spring	1.261	3.52 (0.1–125)	0.489
Other relative	0.898	2.45 (0.57–10.6)	0.231
Unrelated	1.220	3.38 (0.82–14.1)	0.093
Donor/recipient blood group match
Same	–	1
Different	–0.869	0.42 (0.23–0.77)	0.005
Blood transfusion
No	–	1
Yes	–0.451	0.64 (0.39–1.05)	0.075
Ischaemia time, min
<30	–	1
30–60	–0.711	0.491 (0.194–1.27)	0.134
>60	–0.437	0.65 (0.196–2.13)	0.473
Time to diuresis
Immediate	–	1
Delayed	0.473	1.60 (0.58–4.47)	0.366
Induction therapy
No	–	1
Polyclonal	0.217	1.24 (0.361–4.28)	0.731
Monoclonal	–0.271	0.763 (0.262–2.22)	0.619
Maintenance immunosuppression
Conventional	–	1
CsA based	0.278	1.32 (0.74–2.34)	0.343
Tacrolimus	1.855	6.39 (0.76–54)	0.089
Sirolimus	1.536	4.64 (2.14–10)	<0.001
Steroid avoidance	0.589	1.80 (0.386–8.4)	0.454
Steroids in first 3 months, g
<5	–	1
5–10	−0.088	0.92 (0.45–1.89)	0.812
>10	0.631	1.87 (0.78–4.5)	0.158

CsA, cyclosporin A.